The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities
- 241 Downloads
Migraine is among the highest impact illnesses in the global population. Its negative ramifications are personal, social, economic and work related. Research on the development of new preventative migraine therapies has been idle for decades. The introduction, shortly, of an innovative pharmacological class useful for migraine prevention, namely monoclonal antibodies towards calcitonin gene-related peptide or its receptor, opens a new, immense therapeutic scenario. The necessity to manage the chronic and refractory forms of migraine must not take our attention away from the target of the pre-chronic forms. This is the most important target in every study. Indeed, by reducing the evolution towards chronic and consequently refractory chronic migraine, we will reduce complications caused by pharmacological abuse, the serious disability of these devastating chronic states, and the healthcare expenses needed to manage chronicity, abuse and consequent pathologies. We will, lastly, be able to rehabilitate these patients to achieve a quality working and social life, and facilitate their reintegration into daily normality.
Compliance with Ethical Standards
No funding was received for the preparation of this manuscript.
Conflicts of interest
Paolo Martelletti has received fees for participation on advisory boards from Teva, Allergan, Amgen, Novartis, and Electrocore; educational grants from Allergan, ACRAF, and Pfizer; royalties from Springer; research grants from Elytra Pharma, and Sanofi; travel reimbursement from EFIC, EHF and Springer Nature; and an editorial grant from Springer Nature.
- 6.Yuan H et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs 2017, in press, doi: 10.1007/s40259-017-0250-5.
- 7.Stovner LJ, Haimanot RT. Epidemiology of common headache disorders. In: Martelletti P, Steiner TJ, (eds) Handbook of headache. Milan Heidelberg Dordrecht London New York: Springer; 2011. pp. 17–25. SBN 978-88-470-2009-2. doi 10.1007/978-88-470-1700-9.